-
2 weeks ago | 
dermatologytimes.com | Christopher G. Bunick |Kaitlyn Bader
“OX40 and OX40 ligand-targeting biologics are a new entry into the atopic dermatitis therapeutic landscape, and I really had a great time speaking with my friend and colleague, Dr Johann E Gudjonsson, about this topic. I look forward to seeing more data come out on these therapies in the months ahead,” said Christopher Bunick, MD, PhD, in an interview with Dermatology Times.
-
2 weeks ago | 
dermatologytimes.com | Christopher G. Bunick |Kaitlyn Bader
At the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee, new late-breaking data from AbbVie detailed recent real-world data from the CorEvitas Atopic Dermatitis (AD) Registry, providing compelling evidence regarding the effectiveness of upadacitinib in treating moderate to severe AD among adult patients in routine clinical practice.
-
1 month ago | 
dermatologytimes.com | Marie Bosslett |Christopher G. Bunick
Patients with moderate to severe chronic hand eczema (CHE) suffer from a pressing therapeutic gap as no FDA-approved treatments exist, and delgocitinib (LEO Pharma) has not yet been approved in the United States. In an interview with Dermatology Times, Christopher G.
-
1 month ago | 
dermatologytimes.com | Emma Andrus |Christopher G. Bunick
In a recent interview with Dermatology Times, Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine, delved into the evolving treatment landscape of atopic dermatitis (AD). Bunick shared key insights on the distinct mechanisms of action behind emerging biologics and highlighted the ongoing need to raise the bar in achieving optimal treatment outcomes—particularly itch relief and skin clearance.
-
1 month ago | 
dermatologytimes.com | Emma Andrus |Christopher G. Bunick
In a recent interview with Dermatology Times, Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine, broke down the implications of the pivotal LEVEL UP trial for patients with atopic dermatitis (AD). According to Bunick, the study not only reinforced the value of measuring multiple treatment outcomes simultaneously but also introduced a new bar for success that all future therapies should aim to meet.
-
1 month ago | 
dermatologytimes.com | Emma Andrus |Christopher G. Bunick
In an interview with Dermatology Times, Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine, offered perspective on where investigational biologics targeting the OX40 and OX40 ligand (OX40L) pathway may eventually fit into the already complex atopic dermatitis (AD) treatment landscape. “It’s a complicated atopic dermatitis landscape right now,” Bunick said. “We obviously have the oral JAK inhibitors.
-
2 months ago | 
dermatologytimes.com | Emma Andrus |Christopher G. Bunick
In a recent interview with Dermatology Times, Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine, shared insights into the evolving science of biologics for atopic dermatitis (AD)—specifically, the emerging therapeutic potential of targeting the OX40/OX40 ligand pathway. According to Bunick, a critical limitation of current biologic therapies lies in their "monotargeted" approach.
-
2 months ago | 
dermatologytimes.com | Emma Andrus |Christopher G. Bunick
As clinicians look ahead to the upcoming Revolutionizing Atopic Dermatitis (RAD) conference, scheduled for June 6 to 7 in Nashville, Tennessee, one of the much-anticipated lectures is set to be delivered by Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine and Dermatology Times' 2025 editor in chief.
-
Mar 12, 2025 | 
dermatologytimes.com | Kaitlyn Bader |Christopher G. Bunick
“When it comes to oral antibiotics, one of the topics I focused on is the fact that antibiotic stewardship is needed. I also like to say that we are honorary gastroenterologists in dermatology because the antibiotics we prescribe affect the gut. We know that the gut microbiome is so important to human health,” said Christopher Bunick, MD, PhD, in an interview at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.
-
Mar 11, 2025 | 
dermatologytimes.com | Kaitlyn Bader |Christopher G. Bunick
“We have benzoyl peroxide products that are forming benzene, some of them at levels above the conditional limit and are not lasting to the point of the expiration date on the product. This is a regulatory problem. These products are not in line with the FDA regulatory standard, and this is an opportunity for innovation in dermatology,” said Christopher Bunick, MD, PhD, in an interview at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.
